Year: 2005
Type: letter
Abstract: noted a survival benefit from adjuvant chemotherapy in the MSI-negative, or microsatellite-stable, patient group.We therefore hypothesized that a more common phenotype that was nevertheless closely related to the MSI-positive phenotype may be responsible for survival benefit achieved with fluorouracil-based chemotherapy in population-based colorectal cancer trials.At the time, we speculated that this might be the cytosine-phosphate-guanine island methylator phenotype because of known sex and site differences in its frequency; we recently published direct evidence in support of this hypothesis.3 We urge workers in this field to give careful consideration to the site of tumor origin when comparing their results with our earlier observations.It is also important to bear in mind that results obtained with the highly selected and generally younger patients who enter clinical trials may be different than those seen in population-based studies.This is an essential consideration if age-, sex-and tumor-site-related phenomena such as aberrant folate metabolism and DNA methylation are involved in the response to fluorouracil-based therapies.
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2586988269